With inspections still largely in limbo because of the coronavirus pandemic, drug sponsors are wondering how they can assure the US Food and Drug Administration that their facilities are safe for an inspection and break a logjam of delayed product approvals.
One idea was to develop plans to accommodate in-person inspections. Douglas Farquhar, director at Hyman, Phelps and McNamara, said several...





